Medicure Inc. (MCUJF)

Market Cap	8.38M -13.6%
Revenue (ttm)	22.44M +44.3%
Net Income	-4.88M
EPS	-0.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Open	0.7974
Previous Close	0.8327
Day's Range	0.7974 - 0.7974
52-Week Range	0.7055 - 0.9745
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 38
• Stock Exchange: OTCMKTS
• Ticker Symbol: MCUJF

Financial Performance

In 2025, Medicure's revenue was 28.86 million, an increase of 31.72% compared to the previous year's 21.91 million. Losses were -7.10 million, 583.1% more than in 2024.

Financial numbers in CAD